.
MergerLinks Header Logo

New Deal


Announced

Completed

Towa Pharmaceutical completed the acquisition of the generics unit of Esteve for $354m.

Financials

Edit Data
Transaction Value£272m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Acquisition

Friendly

Private

Spain

generic pharmaceuticals

Majority

Pharmaceuticals

Completed

Synopsis

Edit

Towa Pharmaceutical, a company specializing in generic drugs and based in Kadoma, Osaka, completed the acquisition of the generics unit of Esteve, a Spanish pharmaceutical company, for $354m. "I am happy that we can now build a foundation for full-scale overseas expansion by obtaining the sales networks that Pensa owns in Europe and the US, its know-how and knowledge on EMA/FDA regulations and commercial practices in each country, and its production facility in Europe. Our goal is to build a solid global structure by respecting and integrating one another's human resources, culture, and technologies. We will work unitedly as a group to provide Towa's value-added products to patients all over the world," Itsuro Yoshida, Towa President.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US